Researchers develop decision-making tool to benefit patients with HCV

June 18, 2018, Beth Israel Deaconess Medical Center

An estimated 3.5 million people in the United States have chronic hepatitis C (HCV), according to the Centers for Disease Control and Prevention. It is the most common cause for cirrhosis and liver cancer in the United States and the leading indication for liver transplantation. While recently developed direct anti-viral agents (DAAs) have proven to be a highly effective treatment option for many patients with HCV, those with decompensated HCV cirrhosis or liver failure may experience little to no improvement in liver function following eradication of HCV.

Published in the June, 2018, issue of Gastroenterology, BIDMC researchers led a retrospective analysis of four randomized clinical trials focused on the effects of DAA therapies in patients with HCV-associated , and developed a new means of predicting improvement in in response to DAA treatment. The online scoring system, called the BE3A score, assesses 5 baseline factors (body mass index, encephalopathy, ascites and serum levels of alanine aminotransferase and albumin) to provide physicians with a shared decision-making tool to quantify the potential benefits of DAA therapy for patients with decompensated cirrhosis.

"Doctors and patients need to decide when a patient should receive HCV treatment in the setting of decompensated cirrhosis from HCV and whether to treat before, or defer treatment until after liver transplant," wrote study authors Michael P. Curry, MD, Section Chief of Hepatology at BIDMC and Z. Gordon Jiang, MD, a translational investigator at BIDMC's Liver Center. "Our study combined all of the data from smaller studies, allowing us to have a large enough sample size to determine predictors of improvement in liver function. With this analysis, we created a tool for shared decision-making for doctors and patients in this exact clinical scenario. "

Explore further: Treating patients for hepatitis C could reduce the need for liver transplants

Related Stories

Treating patients for hepatitis C could reduce the need for liver transplants

April 14, 2016
A new study presented today demonstrates that patients on the liver transplant list with Hepatitis C virus (HCV) and severe liver damage were more likely to be taken off the list or have their need of a liver transplant reduced ...

Combination therapy successfully treats hepatitis C in patients with advanced liver disease

November 30, 2015
A large multi-center clinical trial has found that a combination of antiviral medications can eradicate hepatitis C infection in more than 90 percent of patients with advanced liver disease. Known as the ASTRAL-4 trial, the ...

All-oral, DAA options for HCV effective and well tolerated in patients with decompensated cirrhosis

April 23, 2015
Interim data presented today at The International Liver Congress 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C (HCV) is well tolerated and highly effective in patients ...

Treatment of HCV allows for sustained removal from the liver transplant waiting list

April 21, 2017
A new European study presented today demonstrated that patients with chronic Hepatitis C virus (HCV) and severe liver damage, taken off the liver transplant list as a result of successful direct-acting antiviral (DAA) therapy, ...

Combination therapy offers new hope for difficult-to-treat patients with chronic hepatitis C

April 23, 2015
Results presented today at The International Liver Congress 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high ...

Sustained virological response to oral hepatitis C virus treatment associated with reduced mortality in Italian cohort

April 13, 2018
Patients with chronic hepatitis C virus (HCV) infection who achieve a sustained virological response (SVR) after direct-acting antiviral agent (DAA) treatment have lower all-cause mortality, according to a real-world study ...

Recommended for you

Broadly acting antibodies found in plasma of Ebola survivors

July 17, 2018
Recent Ebola virus disease (EVD) outbreaks, including the 2013-2016 epidemic that ravaged West Africa and the 2018 outbreak in the Democratic Republic of the Congo, highlight the need for licensed treatments for this often-deadly ...

Childhood abuse linked to greater risk of endometriosis, study finds

July 17, 2018
Endometriosis, a painful condition that affects one in 10 reproductive-age women in the U.S., has been linked to childhood physical and sexual abuse, according to findings published today in the journal Human Reproduction.

Hidden blood in feces may signal deadly conditions

July 17, 2018
(HealthDay)—Even if it's not visible to the naked eye, blood in the stool can be serious—a sign of a potentially fatal disease other than colon cancer, new research suggests.

Why men might recover from flu faster than women

July 17, 2018
Men may recover more quickly from influenza infections because they produce more of a key lung-healing protein, a study from scientists at Johns Hopkins Bloomberg School of Public Health suggests.

Scientists a step closer to predicting epidemics

July 13, 2018
Ecologists at the University of Georgia have taken an important step in their efforts to develop an early warning system for infectious disease outbreaks.

Researchers identify target for novel malaria vaccine

July 13, 2018
A Yale-led team of researchers have created a vaccine that protects against malaria infection in mouse models, paving the way for the development of a human vaccine that works by targeting the specific protein that parasites ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.